Navigation Links
Sohn Conference and Damon Runyon Cancer Research Foundations name first pediatric research fellows
Date:7/17/2012

New York, NY (July 16, 2012) The Damon Runyon Cancer Research Foundation and the Sohn Conference Foundation have named three outstanding young scientists as the first-ever Damon Runyon-Sohn Pediatric Cancer Research Fellows, committing more than half a million dollars to help address a critical shortage of funding for pediatric cancer research.

The Sohn Conference Foundation, dedicated to curing pediatric cancers, announced in January that it was granting $1.5 million to the Damon Runyon Cancer Research Foundation, the leading charity supporting innovative young cancer researchers, to establish the award. It provides funding to basic scientists and clinicians who conduct research with the potential to significantly impact the prevention, diagnosis or treatment of one or more pediatric cancers.

July 2012 Damon Runyon-Sohn Fellows

Lara E. Davis, MD, with her sponsor Charles Keller, MD, at Oregon Health and Science University, Portland, Oregon, seeks to develop individualized, molecularly-targeted cancer therapy for osteosarcoma, a disease that accounts for only 2% of all pediatric cancers but is responsible for over 8% of all pediatric cancer deaths. She will establish primary cell cultures of osteosarcoma tumor samples from patients and identify genetic pathways in each individual sample that can be targeted with therapeutic agents. She will also use computer modeling to design drug combinations that may prevent the development of drug resistance. The goal of the proposed project is to improve osteosarcoma survival while decreasing therapy-related toxicity.

Angela J. Sievert, MD, with her sponsor John M. Maris, MD, at The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, is committed to developing more effective treatments for the many children diagnosed with brain tumors each year. Brain tumors are the leading cause of cancer-related death in children. Mutations in BRAF, an oncogene that can drive cancer growth, are prevalent in pediatric astrocytomas. By studying how mutated BRAF can be targeted by the newest classes of cancer drugs, she hopes to understand why and how these tumors develop in children and which treatments might work best.

Leo Wang, MD, PhD, with his sponsor Amy J. Wagers, PhD, at Dana-Farber Cancer Insitute, Boston, Massachusetts, studies leukemia, which is caused by rapidly and inappropriately dividing blood cells. These quickly proliferating cells derive from leukemia stem cells (LSCs) that are present only in very low numbers and are highly resistant to conventional chemotherapy. The persistence of LSCs is a large part of why high-risk leukemias such as acute myeloid leukemia (AML) are difficult to treat and often fatal. His research focuses on finding the activated protein circuits that are specific to and responsible for the development of LSCs. His goal is to understand what makes LSCs different from normal blood stem cells, and to use that knowledge to develop new and innovative therapies for childhood blood cancers.

"These are some of the best young scientists working in pediatric research today, and they're at a critical juncture in their careers," says William Carroll, MD, chair of the Damon Runyon-Sohn Pediatric Cancer Fellowship Committee and Director of the New York University Cancer Institute. "They need our financial support, and we need their brilliant minds focused on curing childhood cancers. That is why this award and the work that Damon Runyon and Sohn do are so important."

Because cancer occurs less frequently in children and young adults than in the adult population, it does not receive significant funding from either the National Cancer Institute (only four percent of its budget) or the biopharmaceutical industry. As a result, there have been limited advances in recent years in treating these cancers, and fewer scientists are working in this field.

"I am inspired by Damon Runyon's dedication to finding the right projects and young scientists to fund," says Evan Sohn of the Sohn Conference Foundation. "We are all so excited to invest in these new Fellows and the cutting-edge research they're doing on behalf of children and young adults with cancer."


'/>"/>

Contact: Yung S. Lie, Ph.D.
yung.lie@damonrunyon.org
212-455-0521
Damon Runyon Cancer Research Foundation
Source:Eurekalert

Related medicine news :

1. Conference brings global focus to social inequality
2. Experts from John Theurer Cancer Center to participate in the AAMDSIF Patient and Family Conference
3. San Francisco is Hosting EB-5 Conference July 19, 2012
4. True-Dose to Exhibit Liquid Pet Supplements at the Cardinal Health Retail Business Conference in Orlando, FL on July 11-14
5. EASL-AASLD Special Conference on Therapy of Hepatitis C
6. Artisan Business Group hosts EB-5 Conference in California
7. San Francisco EB-5 Conference explores inbound Chinese investments
8. Traumatic brain injury the focus of American Headache Society scientific conference
9. International Nanomedicine Conference bound for Sydney: July 2-4, 2012
10. NOVAtime Solutions to be showcased at Booth #1821 in the upcoming Society for Human Resource Management (SHRM) Annual Conference and Exposition
11. AuntMinnie Begins Live Video Stream of ISCT Conference Proceedings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, ... treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including robotic ... osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, ... M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... the most handsome men, look naturally attractive. Plastic surgery should be invisible.” He ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... for human induced pluripotent stem (iPS) cells and other difficult to transfect cells, ... Cloning Medium. The PluriQ™ G9™ Gene Editing System is a complete ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, InhaleLabs.com ... ingestion of their medication by matching users with high quality water pipes within an ... with no commitment. , Inhale was founded by two brothers, Nick and Mike Hunter, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... , June 23, 2016 Research ... Pharma News Issue 52" report to their offering. ... in influenza treatment creates a favourable commercial environment for MedImmune ... growing patient base that will serve to drive considerable growth ... vaccine would serve to cap sales considerably, but development is ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 If ... Leaders Scholarship is any indication, the future is in ... at www.diabetesscholars.org by the Diabetes Scholars Foundation ... the way of academic and community service excellence. ... since 2012, and continues to advocate for people with ...
Breaking Medicine Technology: